Your browser is no longer supported. Please, upgrade your browser.
Settings
SNTA Synta Pharmaceuticals Corp. daily Stock Chart
SNTA [NASD]
Synta Pharmaceuticals Corp.
Index- P/E- EPS (ttm)-0.40 Insider Own2.60% Shs Outstand135.89M Perf Week-2.56%
Market Cap51.64M Forward P/E- EPS next Y-0.01 Insider Trans-68.84% Shs Float82.87M Perf Month2.70%
Income-54.50M PEG- EPS next Q-0.02 Inst Own15.00% Short Float5.91% Perf Quarter80.95%
Sales- P/S- EPS this Y39.00% Inst Trans-18.25% Short Ratio3.98 Perf Half Y-15.56%
Book/sh0.32 P/B1.19 EPS next Y85.70% ROA-69.50% Target Price1.00 Perf Year-83.26%
Cash/sh0.38 P/C0.99 EPS next 5Y0.00% ROE-97.30% 52W Range0.15 - 2.65 Perf YTD8.57%
Dividend- P/FCF- EPS past 5Y10.50% ROI- 52W High-85.66% Beta1.09
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low153.33% ATR0.04
Employees10 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)52.92 Volatility8.93% 10.28%
OptionableYes Debt/Eq0.05 EPS Q/Q75.10% Profit Margin- Rel Volume0.18 Prev Close0.37
ShortableYes LT Debt/Eq0.00 EarningsMay 09 AMC Payout- Avg Volume1.23M Price0.38
Recom3.00 SMA20-3.74% SMA5018.56% SMA200-51.05% Volume224,000 Change2.70%
Oct-21-15Downgrade ROTH Capital Buy → Neutral $13 → $1
Oct-21-15Downgrade FBR Capital Outperform → Mkt Perform $2
Apr-27-15Reiterated ROTH Capital Buy $20 → $13
Feb-06-15Reiterated ROTH Capital Buy $27 → $20
Mar-13-14Reiterated MLV & Co Buy $10 → $6
Mar-12-14Downgrade Stifel Hold → Sell
Nov-05-13Reiterated MLV & Co Buy $16 → $10
Jun-06-13Reiterated MLV & Co Buy $18.50 → $16
Apr-01-13Reiterated MLV & Co Buy $16 → $18.50
Aug-30-12Initiated Stifel Nicolaus Hold
Jan-05-12Initiated Rodman & Renshaw Mkt Outperform $8
Mar-14-11Reiterated Barclays Capital Equal Weight $2 → $4
Feb-28-11Upgrade Canaccord Genuity Hold → Buy $4.50 → $8
Nov-09-10Initiated MLV Capital Buy $8.50
Aug-26-10Initiated Morgan Joseph Buy $6
May-10-10Upgrade Roth Capital Hold → Buy $4
Feb-19-10Initiated RBC Capital Mkts Sector Perform $5
Feb-17-10Downgrade Roth Capital Buy → Hold $4
Nov-05-09Upgrade Roth Capital Hold → Buy $2 → $4
Feb-27-09Downgrade Wachovia Mkt Perform → Underperform
May-19-16 01:04PM  SYNTA PHARMACEUTICALS CORP Financials
May-16-16 04:00PM  VKTX: Phase 2 Study of VK5211 for Hip Fracture Ongoing; Phase 2 Study of VK2809 for Hypercholersterolemia to Commence in mid-2016
May-11-16 10:13AM  Synta (SNTA) Lowers Q1 Loss Y/Y, Focus on Madrigal Merger +7.69%
May-10-16 09:27AM  Synta reports 1Q loss
08:34AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report
May-05-16 05:58AM  What's in the Cards for Synta (SNTA) This Earnings Season?
May-03-16 08:16AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-22-16 05:26PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Financial Statements a +5.71%
Apr-21-16 09:30AM  The Zacks Analyst Blog Highlights: Medivation, Synta, AbbVie, Gilead and Orexigen +6.06%
Apr-20-16 04:38PM  Biotech Stock Roundup: Medivation Buyout Rumors Resurface, Synta Up on Merger Deal
Apr-17-16 06:45PM  Synta Pharmaceuticals Corp (SNTA): Billionaire Bruce Kovner Buys More Shares at Insider Monkey
Apr-15-16 11:30AM  Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals -7.32%
11:00AM  VKTX: Positive Phase 1b Data Presented for VK2809 in Hypercholestermic Patients; Recent M&A Activity Shows Viking is Significantly Undervalued
08:20AM  Synta's marriage with Pennsylvania drugmaker spurred by actual marriage at bizjournals.com
06:03AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-14-16 05:16PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits +70.83%
02:55PM  $60M deal: Montco and Massachusetts biopharm firms to merge at bizjournals.com
07:00AM  Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company Business Wire
Mar-15-16 08:59AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-K, Annual Report -16.67%
Mar-08-16 10:30AM  What's in Store for Synta (SNTA) this Earnings Season?
Mar-01-16 05:11PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities
Feb-29-16 05:13AM  Edited Transcript of SNTA earnings conference call or presentation 6-Nov-14 3:00pm GMT
Feb-12-16 07:20AM  Two local biotechs that are now valued lower than their bank accounts at bizjournals.com
Jan-07-16 01:02PM  This Company is Up +400% in a Month Accesswire -9.68%
Dec-15-15 07:00AM  4 Small Cap NASDAQ/NYSE Stocks Trading With Heavy Volume Accesswire
Dec-13-15 08:52AM  Here is What Hedge Funds Think About United Community Financial Corp (UCFC) at Insider Monkey
Dec-09-15 04:32PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Nov-29-15 07:34AM  Is Ares Dynamic Credit Allocation Fund Inc (ARDC) Going to Burn These Hedge Funds? at Insider Monkey
Nov-22-15 10:51AM  Is Synta Pharmaceuticals Corp. (SNTA) A Good Stock To Buy? at Insider Monkey
Nov-16-15 10:21AM  News Flash: Wall Street Analysts Can Be Wrong at Motley Fool
Nov-06-15 09:22AM  Synta Q3 Loss Narrower than Expected, to Cut Jobs by 60%
Nov-05-15 05:25PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors
05:20PM  Synta Reports Third Quarter 2015 Financial Results Business Wire
Nov-03-15 04:45PM  Synta (SNTA) Q3 Earnings Preview: What's in the Cards?
Oct-24-15 09:40AM  8 BioPharma Movers That Cannot Be Ignored at 24/7 Wall St.
Oct-23-15 03:00PM  Synta Falls, Stops Ganetespib Late-Stage Lung Cancer Study
Oct-22-15 05:28PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits -9.46%
Oct-21-15 11:25AM  Synta shares plunge as company gives up on trial of lead drug in lung cancer at bizjournals.com -63.73%
Oct-20-15 07:30PM  Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer Business Wire
Oct-16-15 05:23PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material
Oct-08-15 07:30AM  Synta Pharmaceuticals Announces Formation of Expert Oncology Panel Business Wire
Sep-15-15 11:17AM  According to Wall Street, These Small-Cap Biotech Stocks Could Triple at Motley Fool
Sep-09-15 08:00AM  Synta Names Alan C. Rigby, Ph.D. Chief Scientific Officer Business Wire
Sep-08-15 08:00AM  Synta Announces Presentations at the 16th Annual World Conference on Lung Cancer Business Wire
Sep-02-15 04:01PM  Synta to Participate in FBR Second Annual Healthcare Conference Business Wire
Aug-14-15 07:00AM  Guidance & Quarterly Review on Four Biotech Companies Accesswire
Aug-09-15 08:13PM  10-Q for Synta Pharmaceuticals Corp. at Company Spotlight
Aug-07-15 11:07AM  Edited Transcript of SNTA earnings conference call or presentation 6-Aug-15 2:00pm GMT
09:50AM  Synta's Q2 Loss Narrower than Expected, Focus on Pipeline - Analyst Blog
Aug-06-15 10:00AM  Synta Pharmaceuticals Corp Earnings Call scheduled for 10:00 am ET today
08:27AM  Synta (SNTA) Reports Narrower-than-Expected Q2 Loss - Tale of the Tape
07:39AM  Synta reports 2Q loss
07:07AM  Q2 2015 Synta Pharmaceuticals Corp Earnings Release - Before Market Open
07:00AM  Synta Reports Second Quarter 2015 Financial Results Business Wire
06:35AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report
Aug-03-15 04:15PM  What to Expect from Synta (SNTA) this Earnings Season? - Analyst Blog
Jul-30-15 04:01PM  Synta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015 Business Wire
Jun-24-15 03:35PM  Synta Reports Encouraging Preclinical Data on Ganetespib - Analyst Blog
Jun-23-15 08:00AM  Synta Announces Journal Publication Describing Complementary Activity of Hsp90 Inhibition and Immune Checkpoint Blockade for Cancer Therapy Business Wire
Jun-16-15 04:01PM  Synta to Participate in Upcoming Investor Conferences Business Wire
Jun-15-15 07:59AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a
Jun-02-15 09:00AM  Synta Announces Ganetespib Program Updates Business Wire
May-28-15 04:30PM  Synta Announces Presentations at the 2015 ASCO Annual Meeting Business Wire
May-27-15 04:01PM  Synta to Present at the Jefferies 2015 Global Healthcare Conference Business Wire
May-11-15 12:10PM  On the move: New hires and appointments in the local life sciences industry at bizjournals.com
May-10-15 08:11PM  10-Q for Synta Pharmaceuticals Corp. at Company Spotlight
May-07-15 10:00AM  Synta Pharmaceuticals Corp Earnings Call scheduled for 10:00 am ET today
08:27AM  Synta Reports First Quarter 2015 Financial Results at noodls
08:13AM  Synta reports 1Q loss
07:57AM  Synta's (SNTA) Q1 Loss In Line with Expectations - Tale of the Tape
07:07AM  Q1 2015 Synta Pharmaceuticals Corp Earnings Release - Before Market Open
07:00AM  Synta Reports First Quarter 2015 Financial Results Business Wire
06:22AM  SYNTA PHARMACEUTICALS CORP Files SEC form 10-Q, Quarterly Report
May-06-15 08:12PM  10-K for Synta Pharmaceuticals Corp. at Company Spotlight
May-05-15 04:00PM  Will Synta (SNTA) Disappoint this Earnings Season? - Analyst Blog
Apr-30-15 04:57PM  Synta to Host Conference Call and Webcast of First Quarter 2015 Financial Results on May 7, 2015 at noodls -5.46%
04:01PM  Synta to Host Conference Call and Webcast of First Quarter 2015 Financial Results on May 7, 2015 Business Wire
Apr-28-15 06:15AM  Five things you need to know today, including Twitter Boston hiring, tech jobs and Coffee Trike guy's new espresso bar at bizjournals.com
Apr-27-15 10:17AM  Synta Pharmaceuticals names third CEO since March 2014 at bizjournals.com -9.67%
07:39AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
07:36AM  Synta Announces Chen Schor Named President, Chief Executive Officer and Director at noodls
07:30AM  Synta Announces Chen Schor Named President, Chief Executive Officer and Director Business Wire
Apr-16-15 01:35PM  A surge in interest in Synta's cancer drug ahead of key science data at bizjournals.com
12:01PM  Synta Pharmaceuticals (SNTA) Stock Rises Today After Announcing Upcoming Presentations at TheStreet
08:44AM  Synta Pharmaceuticals (SNTA) Catches Eye: Stock Jumps 10.7% - Tale of the Tape
08:28AM  Synta Announces Presentations at the 2015 Annual Meeting of the American Association of Cancer Research at noodls
08:00AM  Synta Announces Presentations at the 2015 Annual Meeting of the American Association of Cancer Research Business Wire
Apr-06-15 05:23PM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits +6.06%
12:01PM  Synta Pharmaceuticals Closes Public Offering of Common Stock at noodls
11:30AM  Synta Pharmaceuticals Closes Public Offering of Common Stock Business Wire
Apr-01-15 06:08AM  SYNTA PHARMACEUTICALS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial St
Mar-31-15 10:04AM  Synta Pharmaceuticals (SNTA) Stock Hits 52-Week Low After Pricing Public Offering at TheStreet -16.74%
09:27AM  Synta Pharmaceuticals Prices Public Offering of Common Stock at noodls
09:15AM  Synta Pharmaceuticals Prices Public Offering of Common Stock Business Wire
Mar-30-15 04:19PM  Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock at noodls
04:01PM  Synta Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
Mar-13-15 10:14AM  Synta's Q4 Loss Narrows Y/Y, Focus on Lung Cancer Drug - Analyst Blog
Mar-12-15 08:30AM  Synta Pharmaceuticals Corp Earnings Call scheduled for 8:30 am ET today
08:25AM  Synta's (SNTA) Q4 Loss In Line with Expectations - Tale of the Tape
07:30AM  Synta reports 4Q loss
Synta Pharmaceuticals Corp. focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its clinical stage drug candidate in oncology is ganetespib, an Hsp90 inhibitor, which is in Phase II clinical trials to evaluate the combination of ganetespib and paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma, including malignant peripheral nerve sheath tumors. The company's drug candidate in its Hsp90-inhibitor Drug Conjugate program is STA-12-8666, which is in preclinical trials for chemotherapy irinotecan. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gollust Keith RDirectorDec 14Sale0.32300,00096,6901,539,169Dec 15 04:34 PM
Gollust Keith RDirectorDec 11Sale0.37300,000111,0301,839,169Dec 15 04:34 PM
Kovner BruceDirectorDec 08Sale0.371,369,639506,766340,970Dec 08 02:09 PM
Kovner BruceDirectorDec 07Sale0.4110041836,985Dec 08 02:09 PM
Kovner BruceDirectorDec 04Sale0.41153,60763,348837,021Dec 08 02:09 PM
Kovner BruceDirectorDec 03Sale0.41262,434108,621892,650Dec 03 05:49 PM
Kovner BruceDirectorDec 02Sale0.43687,603293,744987,690Dec 03 05:49 PM
Kovner BruceDirectorDec 01Sale0.43480,716206,8041,236,705Dec 03 05:49 PM
Kovner BruceDirectorNov 30Sale0.43640,505277,6591,410,796Nov 30 05:23 PM
Kovner BruceDirectorNov 27Sale0.50934,595462,6251,642,755Nov 30 05:23 PM
Kovner BruceDirectorNov 25Sale0.491,503,720733,9661,981,218Nov 30 05:23 PM
Kovner BruceDirectorNov 24Sale0.44538,129237,4762,525,789Nov 24 05:27 PM
Kovner BruceDirectorNov 23Sale0.44635,453277,6292,720,672Nov 24 05:27 PM
Gollust Keith RDirectorNov 17Sale0.41100,00041,4002,885,061Nov 19 06:03 PM
Kovner BruceDirectorNov 17Sale0.42700,618295,6611,101,107Nov 17 05:08 PM
Kovner BruceDirectorNov 16Sale0.4415,5306,7591,801,725Nov 17 05:08 PM
Kovner BruceDirectorNov 13Sale0.43507,788219,5681,817,255Nov 17 05:08 PM
Kovner BruceDirectorNov 12Sale0.47733,564347,7832,325,043Nov 12 05:19 PM
Kovner BruceDirectorNov 11Sale0.501,080,941538,2013,058,607Nov 12 05:19 PM
Kovner BruceDirectorNov 10Sale0.551,397,114769,1114,139,548Nov 12 05:19 PM
Kovner BruceDirectorNov 09Sale0.612,225,0541,354,1685,536,662Nov 12 05:19 PM